Ossiam Raises Holdings in Insulet Co. (NASDAQ:PODD)

Ossiam grew its stake in Insulet Co. (NASDAQ:PODDFree Report) by 56.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 5,913 shares of the medical instruments supplier’s stock after buying an additional 2,145 shares during the quarter. Ossiam’s holdings in Insulet were worth $1,283,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in PODD. Capital Research Global Investors lifted its stake in Insulet by 19.7% in the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock worth $2,056,255,000 after acquiring an additional 1,556,455 shares during the last quarter. Baillie Gifford & Co. purchased a new stake in shares of Insulet during the 4th quarter worth $263,144,000. Norges Bank acquired a new position in shares of Insulet during the fourth quarter worth $227,655,000. William Blair Investment Management LLC increased its holdings in Insulet by 145.1% in the third quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock valued at $116,894,000 after buying an additional 433,884 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Insulet by 56.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock valued at $190,623,000 after buying an additional 316,649 shares during the last quarter.

Insulet Trading Up 0.3 %

NASDAQ PODD opened at $192.04 on Tuesday. The stock has a market capitalization of $13.45 billion, a P/E ratio of 58.19, a P/E/G ratio of 3.45 and a beta of 1.15. The firm has a 50-day moving average price of $174.92 and a 200 day moving average price of $185.48. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $298.95. The company has a quick ratio of 2.75, a current ratio of 3.74 and a debt-to-equity ratio of 1.72.

Insulet (NASDAQ:PODDGet Free Report) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, topping the consensus estimate of $0.39 by $0.34. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The company had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. During the same period in the previous year, the firm earned $0.23 EPS. The business’s revenue was up 23.3% on a year-over-year basis. Equities research analysts expect that Insulet Co. will post 3.11 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective for the company in a research report on Tuesday, May 7th. Raymond James cut their price objective on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Jefferies Financial Group upped their target price on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a report on Friday, May 10th. Redburn Atlantic assumed coverage on Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 target price on the stock. Finally, Canaccord Genuity Group raised their price target on Insulet from $226.00 to $234.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $239.18.

Get Our Latest Analysis on Insulet

Insider Activity

In related news, Director Timothy J. Scannell sold 3,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the completion of the transaction, the director now directly owns 42,586 shares of the company’s stock, valued at approximately $7,703,807.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.47% of the company’s stock.

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Recommended Stories

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.